Abstract | Juvenile-onset fibromyalgia (JFM) is a poorly understood chronic pain condition most commonly affecting adolescent girls. The condition is characterized by widespread musculoskeletal pain and other associated symptoms, including fatigue, nonrestorative sleep, headaches, irritable bowel symptoms, dysautonomia and mood disorders such as anxiety and/or depression. In the past few years, there has been a greater focus on understanding JFM in adolescents. Research studies have provided insight into the clinical characteristics of this condition and its effect on both short-term and long-term psychosocial and physical functioning. The importance of early and effective intervention is being recognized, as research has shown that symptoms of JFM tend to persist and do not resolve over time as was previously believed. Efforts to improve treatments for JFM are underway, and new evidence strongly points to the potential benefits of cognitivebehavioural therapy on improving mood and daily functioning. Research into pharmacotherapy and other nonpharmacological options is in progress. Advancements in the understanding of adult fibromyalgia have paved the way for future studies on diagnosis, assessment and management of JFM. This Review focuses on our current knowledge of the condition, provides an update of the latest research advances, and highlights areas for further study.
Introduction
Chronic pain in children is surprisingly common and affects ~25% of school-aged children, 1,2 some of whom report having chronic widespread pain. 3 Fibromyalgia is thought to represent a more severe manifestation of chronic widespread pain 4 and, although less prevalent than chronic widespread pain, is associated with markedly higher levels of pain and impairment in comparison. Estimates suggest that juvenile-onset fibromyalgia (JFM) affects 2.1-6.1% of school children, [5] [6] [7] mostly adolescent female patients, and patients with JFM constitute a substantial proportion (7-15%) of referrals to paediatric rheumatology clinics. 8, 9 In the past decade, little attention was focused on the proper identification of children who met classification criteria for JFM (also known as juvenile primary fibromyalgia syndrome or JPFS). In 1985, Yunus and Masi 10 proposed the first classification criteria for JFM, which included the hallmark symptoms of widespread muscle and joint pain lasting >3 months with associated symptoms including fatigue, sleep difficulty, anxiety and the presence of painful 'tender points' upon physical examination. Other studies have shown that ACR criteria 11 can also be applied to children and adolescents with JFM. 12, 13 Despite the increased emphasis on creating a better classification system, fibromyalgia remains a contested diagnosis in both adults and children, in part because diagnosis is purely symptom-based, and continuing debate exists about which classification criteria should be used. 14, 15 Even more scepticism exists about the utility of JFM classification in children, 16 perhaps because none of the existing fibromyalgia criteria for adults have been validated in paediatric populations. Nevertheless, ample evidence is available that the syndrome of chronic widespread pain with tender-point sensitivity and the associated features of fibromyalgia (sleep difficulties, fatigue and other symptoms) occurs in adolescents just as it does in adults. 10, 17 The difficulty in diagnosing this condition, particularly in children, can cause a great deal of frustration among patients with JFM (and their parents) when no definitive medical cause and/or explanation for the child's symptoms is provided. This lack of information can lead to a conviction that a more serious underlying disease might be being missed and parents then might seek consultation with multiple specialists. In our experience, when this s cenario is handled in an empathic manner by a physician who is knowledgeable about pain conditions in children, who is able to describe what little is known about JFM whilst reassuring the family that JFM is not known to be a progressive disease or associated with serious medical compli cations, families are much more willing to engage in pain management recommendations.
As noted earlier, the study of JFM is still a fairly new area of research and, until the past few years, rigorous scien tific studies were lacking. However, with burgeoning research developments into the underlying mechanisms of (adult) fibromyalgia, including genetic and neuroimaging studies, clinical trials of pharmaco logical and nonpharmacological approaches for the management of the disease, recognition from funding agencies (such as the NIH) and advocacy from patient groups such as the National Fibromyalgia Association and others, the field of fibromyalgia research has made major strides. Simultaneously, increasing attention has been placed on the public health problem of chronic pain in children, 18, 19 and the quality of paediatric pain research studies has greatly improved. A review of JFM is therefore timely, because in the past 8-10 years, we have developed a clearer understanding of the clinical characteristics of JFM, the substantial influence of JFM on physical and psychosocial functioning, and increased knowledge about treatment approaches for managing this condition.
In 2000, we proposed a biopsychosocial conceptual model for understanding JFM in children and its influence on functioning. 20 We have updated this model based on new research findings ( Figure 1 ) and use this model to guide the organization of this Review of the clinical characteristics of JFM, biological and psychosocial factors associated with the condition and the influence of symptoms on daily function and quality of life.
Clinical characteristics and prognosis
As shown in Figure 1 , JFM is a complex syndrome with the core symptom being persistent widespread musculoskeletal pain, and a number of associated symptoms of chronic fatigue, sleep disturbance, cognitive and mood difficulties, and other somatic manifestations such as headache, dysautonomia, subjective soft tissue swelling and irritable bowel syndrome. 21 In the early stages, these symptoms might not present all at once and patients are often seen by their primary care physicians and multiple specialists (such as gastroenterologists and neurologists) before they are eventually diagnosed with JFM by a rheumatologist or pain physician. Consequently, symptoms might have been present for 2 years or more before patients are correctly identified as having JFM, thus delaying use of appropriate treatments. 22 One complicating factor that can also delay diagnosis of JFM in children is that symptoms might be indicative of so-called growing pains, which are usually benign and self-limited in nature. 23 Furthermore, growing pains can also be associated with joint laxity and accompanied by fatigue or clumsiness in children. 24 Interestingly, a subset of patients with JFM also has underlying joint hypermobility, which seems to contribute to increased pain sensitivity. 25, 26 Although joint hyper mobility has been observed in the context of both growing pains and fibromyalgia and there is some evidence that children with growing pains have lower pain thresholds than children without growing pains, 27 no direct research evidence for a relationship between childhood growing pains and chronic pain in adolescence has been reported. For differential diagnosis purposes, 28 growing pains are more common in younger children (pre-adolescents) and occurs mainly at nighttime and tends to resolve, whereas JFM symptoms are most often identified in adolescence, occur throughout the day and are chronic.
Initial studies indicated a fairly positive long-term prognosis for JFM, with ~70% of children no longer meeting JFM criteria after 2 years.
29, 30 However, these estimates were based on community studies of school children who were not treatment-seeking and might not have had symptoms severe enough to seek medical care. By contrast, studies of clinical populations (that is, recruited from hospital settings) of patients with JFM show a chronic and perhaps fluctuating course, with symptoms persisting for the majority (~70%) of young people with JFM. 9, 31, 32 One controlled study published in 2010 of patients with JFM and matched healthy controls (mean age, 15 years) showed that about 50% of patients with JFM met the full ACR criteria for fibromyalgia at ~4 years follow-up (mean age, 19 years), and >70% had continuing symptoms of pain, fatigue or sleep difficulty. 32 Compared with controls, the JFM group had markedly higher pain levels, reduced quality of life, and elevated anxiety and depressive symptoms, demonstrating that the influence of JFM is lasting and substantial.
Biological mechanisms in pain processing
Our current understanding of the pathophysiology of JFM is limited because of the lack of research in this area. However, considerable advances have been made in the field of adult fibromyalgia and other chronic pain conditions. We will therefore present research findings from the adult literature to illustrate potential underlying mechanisms for JFM, whilst cautioning the reader that one cannot assume that the pathophysiology of JFM is identical to fibromyalgia in adults. To date, several theories about the underlying mechanisms for fibromyalgia have been explored and the evidence points to abnormalities in pain processing, with potential neurological, biochemical, inflammatory, and/or genetic factors involved, notwithstanding psychosocial and environmental influences discussed later. In particular, the roles of the central and peripheral nervous systems have been highlighted, although evidence is far from definitive in explaining the range of symptoms seen in individuals with fibromyalgia.
Normal pain processing
Normal pain processing involves ascending pathways (the largest being the spinothalamic tract) in which Key points ■ Juvenile-onset fibromyalgia (JFM) is a complex chronic pain condition that seems to be one manifestation of a wider spectrum of chronic widespread pain syndromes in children and adolescents ■ JFM can be difficult to diagnose because of overlapping features and associated symptoms including sleep disturbance, fatigue, cognitive difficulties, headaches, abdominal pain, dysautonomia, joint hypermobility and co-occurring mood symptoms ■ JFM is associated with marked difficulties in psychosocial functioning and decreased quality of life, with symptoms tending to persist into late adolescence or early adulthood for the majority of patients ■ The pathophysiology of JFM is poorly understood and underlying factors for symptoms and pain-related impairment might include genetic, neurobiological and psychosocial influences ■ Although currently no 'cure' for JFM exists, cognitive-behavioural therapy and exercise-based interventions are promising treatments for the management of JFM symptoms and restoration of function peripheral nociceptors (sensory fibres) detect and transmit pain signals to the brain, sending messages via the dorsal horn to the thalamic nuclei and somatosensory cortex in the brain. 33 Projections from the spinothalamic tract also facilitate input to the insular cortex and then to the amygdala, prefrontal cortex and anterior cingulate cortex regions. This complex pathway is primarily responsible for the sensory, affective, cognitive and autonomic aspects of pain. 33, 34 Normal pain processing also involves descending pathways, which serve to modulate pain through facilitatory and inhibitory signals via a complex brain network linking the prefrontal cortex, cingulate cortex and insula, the periaqueductal grey and regions of the medulla within the spinal cord. [35] [36] [37] However, in patients with fibromyalgia, neuro imaging studies have shown that these normal ascending and descending pain processes seem to be disrupted or dysfunctional. 36, 38, 39 Central sensitization Central sensitization resulting from increased dorsal horn activity and exaggerated responses to both painful and nonpainful stimuli has been hypothesized to be a potential underlying mechanism for pain sensitivity in adults with fibromyalgia or other chronic pain conditions. The increased central sensitivity to pain has been implicated in the atypical response to both mild touch (allodynia) and minimal pressure (hyperalgesia), two frequently noted clinical findings in patients with fibromyalgia, but also in patients with localized or complex regional pain syndromes. 40 The notion that central sensitization describes the aberrant pain pathway in fibromyalgia is supported by studies on the concept of temporal summation of pain, or 'wind up' , which refers to an inability to attenuate the pain resulting from repeated exposure to a noxious stimulus through descending processes (endogenous inhibition) from the cortical areas of the brain. 41, 42 Interestingly, central sensitivity to pain is potentially reversible; whether it is possible in patients with fibromyalgia remains unknown. 43 
Neurochemical factors
Neurochemical factors contributing to the abnormal processing of pain in adult patients with fibromyalgia include increased levels of neurotransmitters thought to be pro-nociceptive, such as substance P 44, 45 and glutamate, 46 ,47 which might serve to heighten pain sensitivity. Similarly, studies have found a decrease in levels of inhibitory neurotransmitters (5-hydroxytryptamine [serotonin] and noredrenaline) in patients with fibromyalgia, which would normally attenuate the nociceptive response. 48, 49 Additional biochemical changes, including findings of a fourfold increase in levels of nerve growth factor (an important stimulator of substance P) within the cerebrospinal fluid of patients with fibromyalgia, 50 further supports the phenomenon of central sensitization. Lastly, levels of dopamine, a key player in natural analgesia within the brain, also seems to be reduced in patients with fibromyalgia. 51, 52 Stress-adaptation response The stress-adaptation response, specifically the h ypothalamic-pituitary axis (HPA), might also be altered in fibromyalgia. This neuroendocrine axis is critical for the stimulation of adrenocorticotropic hormone and the subsequent production of cortisol, which has been noted to be present at diminished levels in patients with fibromyalgia. 53, 54 Interestingly, 5-hydroxytryptamine regulates the HPA axis; therefore, theories imply that the dysfunction of one often leads to dysfunction in the other. Another potentially key neuroendocrine factor is growth hormone, which is important for tissue repair; primarily produced during delta (stage 3 and 4) sleep and, therefore, the chronic disruption of sleep in patients with fibromyalgia might lead to low levels. 55, 56 A few studies have implicated the role of inflammatory cytokines, in particular, the work of Feng et al., 57 in chronic widespread pain and fibromyalgia. [57] [58] [59] [60] [61] [62] [63] These findings could indicate an immune-mediated process in the development of fibromyalgia; however, the data are still not definitive and additional studies are needed.
Biologic factors
Neurobiology-alterations in pain processing pathways Neuroendocrine (serotonin, substance P, glutamate) HPA Environment Sedentary lifestyle Family and/or parent pain history Stress and/or trauma Negative effects Decreased physical function School absences Activity avoidance Dif culties in peer relationships Dif culties in family relationships Poor coping Decreased quality of life Genetic in uences Serotonin transporter gene Dopamine receptor genes Catecholamine (COMT) HLA linkage Ampli ed widespread pain Central sensitization Wind-up Fatigue Sleep dif culties Cognitive dif culties Autonomic disturbance Dysautonomia Mood symptoms Anxiety Depression Other somatic symptoms e.g.
Gender and genetic influences
Lastly, gender and genetic influences in fibro myalgia have been identified, although much work is still needed in this area. Although no studies have directly assessed gender differences in JFM, the predominance of adolescent female patients who present with JFM in a clinical setting is noteworthy. 10, 13, 22, 64 In the adult fibromyalgia literature, a higher prevalence of fibromyalgia in women clearly exists, 65 and differences were more often noted among women than men in terms of the number of tender points and tender point scores, fatigue and number of associated symptoms. 66, 67 Family aggregation studies have indicated that fibromyalgia is more common among female relatives and the strong association of fibromyalgia among family members [68] [69] [70] suggests a genetic basis for this condition. Some studies have suggested a link between HLA and fibromyalgia, with a greater association of fibromyalgia symptoms at the HLA region, in particular HLA-DR4. 71, 72 In addition, studies have noted various gene poly morphisms associated with 5-hydroxytryptamine (5-HTT transporter gene, SLC6A4), 73, 74 dopamine (D2 and D4 receptor genes 75, 76 ) and catecholamines (catechol-O-methyltransferase, COMT 77 ) in fibro myalgia. Despite several studies implicating genetic causes, a study of Finnish 11-year-old twins found widespread pain in 9.9%, with discordance among twins. The authors suggest that a stronger environ mental influence might be at play in the development of chronic pain. 78 Certainly, this complex condition involves several biological, genetic and potential environmental factors that might be maintained or heightened by psychosocial inputs. Identification of the underlying mechanisms of fibromyalgia, and especially the specific vulnerabilities that predispose individuals to develop juvenile-onset of symptoms is of great importance. Whether these factors operate in the same way in young patients with JFM and whether they might be reversible, especially in developing nervous systems with potentially greater plasticity, is currently unknown.
Psychosocial factors and functioning
The effect of JFM on the lives of the patients and their families is substantial. Patients with JFM report marked pain-related disability, including difficulties in daily physical functioning, 13, 22, 79, 80 and decreased quality of life that are even more severe than those reported by patients with other chronic paediatric pain or rheumatic diseases. [81] [82] [83] Objective physical activity monitoring has documented that adolescents with JFM become very sedentary 84 and are, therefore, at greater risk of deconditioning and further risk of inactivity. School absenteeism is common, with adolescents missing an average of three school days per month 85 and several of them are unable to attend regular school at all (that is, homeschooled) owing to JFM symptoms. Perhaps not surprisingly, adolescents with JFM are seen by their classmates (and themselves) as being isolated, more emotionally sensitive than their healthy peers, and have fewer friendships. 86 Heightened levels of emotional distress and even comorbid psychiatric conditions are not uncommon, particularly elevated anxiety; over 50% of patients with JFM met criteria for an anxiety disorder in one study. 87 Although the severity of depressive symptoms are somewhat higher in patients with JFM than in healthy individuals, 12 ,80 the presence of major depression is lower than has been reported in adults with fibromyalgia. 87 The lifetime prevalence of major depression is estimated to be 26% in children with JFM 83 and 61.5% in adults with fibromyalgia. 88 A study on the family environment of children with rheumatic diseases including patients with JFM shows that these individuals have a greater likelihood of having family members who also have chronic pain, 89 and mothers of patients with JFM were more than four times as likely to have fibromyalgia than mothers of healthy adolescents. 90 Although these aspects might be a reflection of potential genetic influences, evidence also exists that learning factors-such as maladaptive coping responses to pain (particularly the use of catastrophic thinking, which might be more common in families in which a parent also suffers from chronic pain-might lead to increased pain and greater pain interference in adolescents. 89 In general, families of adolescents with JFM have reported poorer overall family functioning and more conflicted relationships. 90 Interestingly, a family environment that is more controlling-that is, one that does not facilitate autonomy and independence in the early years-might have long-term consequences for adolescents with JFM, resulting in higher risk of d epressive symptoms later on in life. 91 Taken together, these findings highlight the complex relationships between JFM, the disruptive effect of symptoms on physical and emotional functioning, and the potential for these factors to interact with one another and maintain symptoms and disability over time (as illustrated in Figure 1 ). Despite the complexities, research is beginning to point the way towards potentially modifiable areas, which might benefit from intervention and better management of the disease. For young people with JFM, early intervention is particularly important as it has the potential to avoid the long-term negative effects on quality of life, mood and functioning into the adult years.
Treatment and management

Pharmacological management
Evidence-based guidelines for the pharmacological management of JFM are lacking and currently no FDAapproved drugs are available for JFM. However, paediatric clinical trials evaluating the safety and efficacy of medications already approved for use in adults with fibromyalgia are ongoing (clinicaltrials.gov: duloxetine NCT01237587 and pregabalin NCT01020474).
92,93 The 5-hydroxytryptamine-noredrenaline reuptake inhibitors (SNRIs) duloxetine and milnacipran seem to be effective at decreasing pain and clinical fibromyalgia symptoms in adults: 94, 95 in a Cochrane review published in 2013, at least a 50% reduction of pain among 280 of 1,000 adults with fibromyalgia was recorded compared with 192 of 1,000 healthy individuals as controls (RR 1.49, CI 1.35-1.64). However, it was also observed that SNRIs have limited efficacy for several adults with fibromyalgia owing to adverse effects such as nausea and insomnia, and other difficulties. 96 Whether these medications will be safe and efficacious for use in children is not yet known. Pregabalin, a γ-aminobutyric acid a nalogue, is an antiepileptic drug that has been found to be useful for pain reduction in adults with fibromyalgia. 97 Pregabalin, and a similar compound, gabapentin, have been approved for the treatment of neuropathic pain. In our clinical experience, gabapentin has been used off-label with some success for the treatment of JFM. These anti convulsant medications might work by decreasing neuron excitability via binding to the α2-δ subunit of the voltagegated calcium channels on nerves. 98 Understanding the mechanisms of action of these drugs can be useful in fibromyalgia and could help unravel the underlying pathophysiology of the disease itself. Clinical practice for the treatment of JFM (though not necessarily evidencebased) has been primarily aimed at targeting the major associated symptoms, particularly pharmacological treatments aimed at restoring sleep and minimizing mood disorders. Medical treatments for dysmenorrhoea, irritable bowel syndrome, headaches, dysautonomia or postural orthostatic hypertension are frequently used to minimize pain triggers.
Additional off-label medications used in the treatment of JFM include the tricyclic antidepressant amitrip tyline, and the structurally similar muscle relaxant, cyclobenzaprine. As with SNRIs, tricyclic anti depressants function by inhibiting 5-hydroxytryptamine and noredrena line reuptake; however, in general, tolerability can be worse. Selective 5-hydroxytryptamine reuptake inhibitors (SSRIs) have had less convincing evidence for efficacy in adults with fibromyalgia. [99] [100] [101] [102] Use of opioids and narcotics should be avoided in treating JFM, particularly given the lack of research in adult fibromyalgia and the potential for dependency and abuse. It should be noted that tramadol (a μ-opioid receptor agonist and SNRI) might be beneficial in a subset of patients resistant to other therapy. 103 Little evidence exists of efficacy with respect to NSAIDs alone for the treatment of f ibromyalgia or JFM.
Psychological intervention
Cognitive-behavioural therapy (CBT) is a behavioural intervention that has been well-studied in the treatment of chronic pain in children, 104, 105 and has been found to be effective in reducing disability and depressive symptoms in youth with JFM. 22, 106, 107 The treatment is usually delivered by a trained psychologist in a 6-8 weekly session format and the focus is to train patients to manage pain using active and adaptive coping skills. These include the use of relaxation-based treatments, distraction, activity pacing, scheduling pleasant activities, problem solving, and replacing negative and catastrophic thoughts with more calming and realistic appraisals. For children and adolescents with pain, parents are usually included in some sessions to provide parents with guidance and training in how to be a good 'coach' for their child so that they can support the use of these skills in the home. Our trial of CBT specifically for adolescents with JFM, published in 2012, 22 showed strong efficacy of coping skills training in improving daily functioning and mood, and that the treatment effects lasted >6 months. The advantages of CBT are that it was found to be safe, not associated with any adverse reactions, and well-received by patients and families, with 85% of patients completing the full course of therapy. 22 In our experience, CBT is best used in the context of a multidisciplinary treatment regimen, which incorporates pharmacological, behavioural and exercise-based approaches for optimal effect on pain and functioning. Not all pain treatment centres have a psychologist or therapist trained in CBT for pain management, although efforts to make CBT more accessible to young patients with chronic pain via online-based interventions have been taken, and early findings seem to show positive results. 108, 109 Whether adolescents with JFM, who generally present as more complex from a physical and psychological perspective than children with other pain conditions (such as recurrent headache or abdominal pain), benefit as much from distance learning therapies as those with less-disabling conditions is currently unclear. The potential limitation of online approaches is that they might not be of sufficient intensity or enable as much tailoring of content as might be required for patients with JFM.
Exercise-based approaches
In adults, numerous studies have documented the benefits of aerobic exercise and strength training for reducing pain in adults with fibromyalgia, [110] [111] [112] [113] and guidelines published by the American Pain Society recom mend at least 30 min of vigorous exercise 2-3 times per week for individuals with fibromyalgia (adults and children). Unfortunately, long-term adherence and sustained moti vation for exercise programmes can be quite poor and, consequently, the benefits of treatment disappear over time. 114 One study has shown that aerobic exercise is a promising intervention for adolescents with JFM in the short term (12 weeks), 115 but longer-term studies are needed to evaluate the sustainability of these treatment gains. Research findings show that patients with JFM become sedentary 84 and show alterations in body biomechanics, that is, in gait, posture and strength, 116 which, when combined with overall physical deconditioning, place them at increased risk of pain and/or injury when they do begin to exercise. Moreover, adults with fibromyalgia have been shown to have difficulties with stability and are more than three times at risk of falls than healthy individuals, 117, 118 which underscores that exercise programmes should be carefully designed. More tailored approaches that match exercise inter ventions to the specific needs of patients with JFM might be needed. For example, it has been proposed that a programme of neuromuscular training, based upon paediatric exercise science principles that use injury-prevention techniques used by Sports Medicine specialists with teenage athletes, could be modified for use in chronic pain rehabilitation. 115 This type of training first teaches patients with JFM how to exercise safely, whilst minimizing delayedonset muscle soreness (which might mimic fibromyalgia symptoms), and increasing their confidence in movement by improving their gait, posture, balance and functional movements. This new approach is currently being tested in a small-scale clinical trial by our research group to see if neuromuscular training, when combined with psychological coping skills training, facilitates increased activity levels and more engagement with vigorous e xercise in adolescents with JFM. 119 
Conclusions
Over the past decade, much progress has been made in our understanding of JFM. Evidence exists that JFM symptoms and clinical characteristics are remarkably similar to adult fibromyalgia, and are similarly d isabling and associated with marked reductions in quality of life. Symptoms tend to persist into adulthood for the majority of patients. Promising approaches to the treatment of JFM are being developed and CBT seems to have good evidence for helping patients cope with JFM and function more normally. However, relative to the burgeon ing literature in adult fibromyalgia, research in JFM still lags behind and prevailing myths about the proper identifi cation and management of this childhood condition still exist. Rigorous studies are still needed to address a number of unmet needs: to validate JFM classification criteria for research and clinical use in paediatric populations; to examine the prognosis with specific attention to similarities and differences between juvenile-onset and adult-onset fibromyalgia; to understand the underlying mechanisms of JFM (in particular, genetic and neuro biological underpinnings), to guide research into promising pharmacological treatments; and to refine psychological, exercise-based and combined self-management interventions and methods of delivery that improve long-term adherence to these recommendations. Many of these efforts are underway, and it is hoped that in the coming years there will be major advances in our ability to effectively diagnose and treat this complex condition early in its course to prevent continuing s uffering and disability into adulthood.
Review criteria
We searched for original articles and review papers focusing on juvenile fibromyalgia in MEDLINE, PubMed and Google Scholar published between 1985 and 2013. The search terms used were "fibromyalgia", "juvenile fibromyalgia", "chronic widespread pain", "pathophysiology", "psychosocial factors", "treatment", "cognitive-behavioural therapy", "physical therapy", and "pharmacotherapy". All papers identified were English-language, full-text papers. We also searched the reference lists of identified papers for further papers.
